Diego M Fernandez-Aroca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8473672/publications.pdf

Version: 2024-02-01

8 papers

147 citations

1477746 6 h-index 1588620 8 g-index

8 all docs 8 docs citations

8 times ranked 285 citing authors

#	Article	IF	CITATIONS
1	p38 \hat{i}^2 (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models. Radiotherapy and Oncology, 2021, 156, 136-144.	0.3	7
2	Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential. Journal of Inorganic Biochemistry, 2021, 218, 111403.	1.5	7
3	ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. Journal of Cellular and Molecular Medicine, 2021, 25, 10591-10603.	1.6	7
4	$p38\hat{l}^2$ and Cancer: The Beginning of the Road. International Journal of Molecular Sciences, 2020, 21, 7524.	1.8	14
5	P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. Cancer Letters, 2019, 451, 23-33.	3.2	44
6	Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. PLoS ONE, 2018, 13, e0200878.	1.1	26
7	E1a is an exogenous inÂvivo tumour suppressor. Cancer Letters, 2017, 399, 74-81.	3.2	9
8	p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. Frontiers in Cell and Developmental Biology, 2016, 4, 69.	1.8	33